Including the present study, three different small molecular mitofusin activators (trans-MiM111, CPR1-B, 8015) have improved neuromuscular function in the mouse model of CMT2A provoked by motor neuron-specific transgenic expression of human MFN2 T105M (Franco et al., 2020, 2022). This evidence concerns the gene MFN2 and Charcot-Marie-Tooth disease type 2A1.